Date: May 30, 2013 Author: Samantha Liss Source: bizjournals (
click here to go to the source)
Vasculox, a St. Louis-based startup focused on developing drugs for transplantation and pulmonary hypertension, was awarded $827,018 from the National Heart, Lung and Blood Institute.
Last year, Vasculox was awarded $706,733 from the National Heart, Lung and Blood Institute and received $203,191 in 2009 for a total of $1.7 million to date.
Vasculox also has received $150,000 from the Missouri Innovation, Development and Entrepreneurship Advancement (IDEA) program, a state program that makes equity investments in startup companies based in Missouri.
Vasculox, led by President and CEO Bob Karr, is a portfolio company of BioGenerator, the non-profit venture development organization of BioSTL.
